Par Drugs And Chemicals enterprise value

·UnclassifiedChart ›

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


149	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
36.4	41.8	27.6	36.7	22.2
112	—	—	—	—
−36.4	−41.8	−27.6	−36.7	−22.2
₹91.15	—	—	—	—

119	112	99.0	85.6	71.2

1.04×	—	—	—	—
6.10×	—	—	—	—
7.67×	—	—	—	—
7.75×	—	—	—	—
108	104	101	95.6	95.7
18.4	17.1	19.5	22.8	18.2
14.6	13.4	15.9	19.4	15.0
—	16.4	16.2	20.2	13.4
14.5	14.5	14.9	14.2	5.7
—	14.4	14.9	14.1	5.7
—	2.0	1.3	6.1	7.6

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

PAR₹120.70

Par Drugs And Chemicals Limited

· Unclassified

₹ CrorePeersBALAXI CROWN STEELCITY HINDCON LATTEYS HECPROJECT AIROLAM GROBTEAMcap ₹149 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	148.5
- Cash, Equiv & ST Investments	22.2	36.7	27.6	41.8	36.4
Enterprise Value	—	—	—	—	112.2
Net Debt (memo)	-22.2	-36.7	-27.6	-41.8	-36.4
EV per Share	—	—	—	—	91.15

Total Capital	71.2	85.6	99.0	112.0	119.3

EV/Sales	—	—	—	—	1.04
EV/EBITDA	—	—	—	—	6.10
EV/EBIT	—	—	—	—	7.67
EV/Free Cash Flow	—	—	—	—	7.75
Reference Items — Trailing FY Values
Sales	95.7	95.6	101.0	103.7	107.7
EBITDA	18.2	22.8	19.5	17.1	18.4
EBIT	15.0	19.4	15.9	13.4	14.6
Operating Cash Flow	13.4	20.2	16.2	16.4	—
Free Cash Flow	5.7	14.2	14.9	14.5	14.5
FCFF (free cash flow to the firm)	5.7	14.1	14.9	14.4	—
Capital Expenditure	7.6	6.1	1.3	2.0	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.